相似文献
1
Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu Positive Allosteric Modulator Tool Compound.
ACS Med Chem Lett. 2020 Aug 20;11(9):1773-1779. doi: 10.1021/acsmedchemlett.0c00432. eCollection 2020 Sep 10.
2
Persistent challenges in the development of an mGlu PAM in vivo tool compound: The discovery of VU6046980.
Bioorg Med Chem Lett. 2023 Jan 15;80:129106. doi: 10.1016/j.bmcl.2022.129106. Epub 2022 Dec 15.
3
Discovery of VU6005649, a CNS Penetrant mGlu Receptor PAM Derived from a Series of Pyrazolo[1,5-]pyrimidines.
ACS Med Chem Lett. 2017 Sep 1;8(10):1110-1115. doi: 10.1021/acsmedchemlett.7b00317. eCollection 2017 Oct 12.
4
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).
J Med Chem. 2019 Feb 14;62(3):1690-1695. doi: 10.1021/acs.jmedchem.8b01810. Epub 2019 Jan 17.
5
Surveying heterocycles as amide bioisosteres within a series of mGlu NAMs: Discovery of VU6019278.
Bioorg Med Chem Lett. 2019 May 15;29(10):1211-1214. doi: 10.1016/j.bmcl.2019.03.016. Epub 2019 Mar 15.
6
Discovery of a novel, CNS penetrant M PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.
Bioorg Med Chem Lett. 2017 Sep 15;27(18):4274-4279. doi: 10.1016/j.bmcl.2017.08.043. Epub 2017 Aug 20.
7
Design and Synthesis of -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu NAMs.
ACS Med Chem Lett. 2017 Aug 15;8(9):925-930. doi: 10.1021/acsmedchemlett.7b00249. eCollection 2017 Sep 14.
8
Discovery of "Molecular Switches" within a Series of mGlu Allosteric Ligands Driven by a "Magic Methyl" Effect Affording Both PAMs and NAMs with Activity, Derived from an M PAM Chemotype.
ACS Bio Med Chem Au. 2021 Aug 20;1(1):21-30. doi: 10.1021/acsbiomedchemau.1c00024. eCollection 2021 Dec 15.
9
Discovery of VU6007496: Challenges in the Development of an M Positive Allosteric Modulator Backup Candidate.
ACS Chem Neurosci. 2024 Sep 18;15(18):3421-3433. doi: 10.1021/acschemneuro.4c00508. Epub 2024 Aug 28.
引用本文的文献
1
Profiling the Impact of mGlu/Elfn1 Protein Interactions on the Pharmacology of mGlu Allosteric Modulators.
ACS Chem Neurosci. 2025 Aug 6;16(15):2872-2886. doi: 10.1021/acschemneuro.5c00174. Epub 2025 Jul 21.
2
Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome.
J Pharmacol Exp Ther. 2025 Jun;392(6):103602. doi: 10.1016/j.jpet.2025.103602. Epub 2025 May 8.
3
mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders.
Pharmacol Rep. 2024 Dec;76(6):1219-1241. doi: 10.1007/s43440-024-00657-7. Epub 2024 Sep 30.
4
Therapeutic Potential for Metabotropic Glutamate Receptor 7 Modulators in Cognitive Disorders.
Mol Pharmacol. 2024 Apr 17;105(5):348-358. doi: 10.1124/molpharm.124.000874.
5
Differential Activity of Orthosteric Agonists and Allosteric Modulators at Metabotropic Glutamate Receptor 7.
Mol Pharmacol. 2023 Jul;104(1):17-27. doi: 10.1124/molpharm.123.000678. Epub 2023 Apr 27.
6
GRM7 gene mutations and consequences for neurodevelopment.
Pharmacol Biochem Behav. 2023 Apr;225:173546. doi: 10.1016/j.pbb.2023.173546. Epub 2023 Mar 30.
7
Design and Synthesis of New Quinazolin-4-one Derivatives with Negative mGlu Receptor Modulation Activity and Antipsychotic-Like Properties.
Int J Mol Sci. 2023 Jan 19;24(3):1981. doi: 10.3390/ijms24031981.
8
Persistent challenges in the development of an mGlu PAM in vivo tool compound: The discovery of VU6046980.
Bioorg Med Chem Lett. 2023 Jan 15;80:129106. doi: 10.1016/j.bmcl.2022.129106. Epub 2022 Dec 15.
本文引用的文献
1
Synthesis and SAR of a series of mGlu NAMs based on an ethyl-8-methoxy-4-(4-phenylpiperazin-1-yl)quinoline carboxylate core.
Bioorg Med Chem Lett. 2020 Nov 15;30(22):127529. doi: 10.1016/j.bmcl.2020.127529. Epub 2020 Sep 2.
2
Surveying heterocycles as amide bioisosteres within a series of mGlu NAMs: Discovery of VU6019278.
Bioorg Med Chem Lett. 2019 May 15;29(10):1211-1214. doi: 10.1016/j.bmcl.2019.03.016. Epub 2019 Mar 15.
3
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).
J Med Chem. 2019 Feb 14;62(3):1690-1695. doi: 10.1021/acs.jmedchem.8b01810. Epub 2019 Jan 17.
4
Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders.
Front Mol Neurosci. 2018 Oct 23;11:387. doi: 10.3389/fnmol.2018.00387. eCollection 2018.
5
VU6010608, a Novel mGlu NAM from a Series of -(2-(1-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides.
ACS Med Chem Lett. 2017 Nov 8;8(12):1326-1330. doi: 10.1021/acsmedchemlett.7b00429. eCollection 2017 Dec 14.
6
Discovery of VU6005649, a CNS Penetrant mGlu Receptor PAM Derived from a Series of Pyrazolo[1,5-]pyrimidines.
ACS Med Chem Lett. 2017 Sep 1;8(10):1110-1115. doi: 10.1021/acsmedchemlett.7b00317. eCollection 2017 Oct 12.
7
mGlu potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome.
Sci Transl Med. 2017 Aug 16;9(403). doi: 10.1126/scitranslmed.aai7459.
8
Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152 Consanguineous Families With Neurodevelopmental Disorders.
JAMA Psychiatry. 2017 Mar 1;74(3):293-299. doi: 10.1001/jamapsychiatry.2016.3798.
9
Exome sequencing in mostly consanguineous Arab families with neurologic disease provides a high potential molecular diagnosis rate.
BMC Med Genomics. 2016 Jul 19;9(1):42. doi: 10.1186/s12920-016-0208-3.
10
Phasic and Tonic mGlu7 Receptor Activity Modulates the Thalamocortical Network.
Front Neural Circuits. 2016 Apr 25;10:31. doi: 10.3389/fncir.2016.00031. eCollection 2016.
Zotero 插件